Casio Computer has launched its uterocervical observation camera, DZ-C100 COLPOCAMERA, and camera stand, CST-100M, in the US, Australia, and New Zealand.
The DZ-C100 COLPOCAMERA is designed for uterocervical observation and photography in gynaecological settings while the CST-100M camera stand is designed for ease of operability and convenience.
Related: FDA panel gives go-ahead to Lumicell’s breast cancer detection tool
This launch comes following the successful registrations with the Food and Drug Administration (FDA) in the US, and Therapeutic Goods Administration (TGA) in Australia.
The camera, which aids in the early detection of cervical cancer, is designed for gynaecological examinations. It can capture high-definition images in three modes with a single shutter click.
Initially introduced in Japan in March 2022, the DZ-C100 COLPOCAMERA and CST-100M stand facilitate the early detection of cervical cancer.
The camera is capable of capturing three types of images – normal, green, and polarised images.
Following its European debut in September 2023, the DZ-C100 has garnered positive feedback from medical professionals for its high-definition imaging capabilities and user-friendly Touch Focus Function, Casio said.
This feature simplifies the process of focusing images displayed on the camera’s LCD monitor.
The FDA has classified the DZ-C100 and CST-100M as Class II medical devices while the TGA has designated them as Class I medical devices.
These products have been registered in New Zealand’s WAND Database.
Casio America, the company’s US sales subsidiary; and C R KENNEDY & Company, its distributor in Australia and New Zealand, are responsible for the products’ sales.
In a press statement, Casio said: “Now expanding the reach of COLPOCAMERA to the US, Australia and New Zealand, Casio continues to grow its medical device business, contributing to the medical field around the world.”
